Trials / Unknown
UnknownNCT05765968
Cumulative Live Birth After Double Stimulation Protocol Versus Antagonist Protocol for Poor Ovarian Responders
Cumulative Live Birth Rates in the Same Cycle Double Stimulation Protocol Versus a Two-cycle Antagonist Stimulation Protocol in IVF Patients With a Poor Prognosis: a Randomized Clinical Trial
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 1,198 (estimated)
- Sponsor
- Shandong University · Academic / Other
- Sex
- Female
- Age
- 20 Years
- Healthy volunteers
- Accepted
Summary
To compare the difference in cumulative live birth rates within one year between double stimulations protocol and two-cycle antagonist protocol in poor ovarian responders.
Detailed description
The theory of multicyclic development of follicles during the menstrual cycle prompted new approaches to ovarian stimulation such as double stimulation within the same menstrual cycle, in both follicular and luteal phases. The double ovarian stimulation protocol has been proposed to optimize the number of oocytes retrieved within the shortest possible timeframe.In general, the aim of DUOSTIM is to obtain the highest number of oocytes in the shortest time, thus avoiding waste of time, which is crucial for these patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Double Stimulation Protocol | cummulative live birth outcome after two cycles of in virto fertilization using double stimulation protocol, which refers to two cycles of ovarian stimulation in both follicular phase and luteal phase within the same menstrual cycle |
| PROCEDURE | Antagonist Stimulation Protocol | cummulative live birth outcome within no more than two cycles of in virto fertilization using classical antagonist protocol |
Timeline
- Start date
- 2023-03-14
- Primary completion
- 2026-03-01
- Completion
- 2026-04-01
- First posted
- 2023-03-13
- Last updated
- 2023-03-14
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05765968. Inclusion in this directory is not an endorsement.